Prediction of drop-out and functional impairment in recent-onset schizophrenia spectrum disorders. (13th April 2021)

• Record Type: Journal Article
• Authors: Mucci, A.; Bucci, P.; Winter Van Rossum, I.; Arango, C.; Baandrup, L.; Glenthøj, B.; Dazzan, P.; Demjaha, A.; Mcguire, P.; Díaz-Caneja, C. Martínez; Leucht, S.; Rodriguez-Jimenez, R.; Kahn, R.; Galderisi, S.
• Is Part Of: European psychiatry. Volume 64:Supplement 1(2021)
• Page Start: S35
• Page End: S36
• Publication Date: 2021-04-13
• Subjects: First-episode schizophrenia -- Functional Outcome -- Persistent negative symptoms; Psychiatry -- Periodicals; Mental illness -- Periodicals; Electronic journals; 616.89
• DOI: 10.1192/j.eurpsy.2021.123
• Languages: English
• ISSNs: 0924-9338

Abstract

Abstract : Persistent negative symptoms are associated with worse outcome in both first-episode and chronic subjects with schizophrenia. The identification of these symptoms in recent-onset subjects is still controversial as retrospective data are often unavailable. The prospective assessment of persistence of negative symptoms might represent a valid alternative but the length of the persistence is still to be established. The present study investigated the prevalence of negative symptoms of moderate severity, unconfounded by depression and extrapyramidal symptoms at baseline in a large cohort of patients in the early stage of a schizophrenia-spectrum disorder, recruited to the OPTiMiSE trial. Persistent unconfounded negative symptoms were assessed at 4, 10 and 22 weeks of treatment. Symptomatic remission, attrition rate and psychosocial functioning was evaluated in subjects with short-term (4 weeks) persistent negative symptoms (PNS) and in those with negative symptoms that did not persist at follow-up and/or were confounded at baseline (N-PNS). Negative symptoms of moderate severity were observed in 59% of subjects at baseline and were associated to worse global functioning. PNS were observed in 7.9% of the cohort, unconfounded at both baseline and end of 4-week treatment. PNS subjects showed lower remission and higher attrition rates at the end of all treatment phases. Fifty-six percent of subjects completing phase 3 (clozapine treatment) had PNS, and 60% of them were non-remitters at the end of this phase. The presence of short-term PNS during the first phases of psychosis was associated with poor clinical outcome and resistance to antipsychotic treatment, including clozapine. Disclosure: Prof Mucci has been a consultant and/or advisor to or has received honoraria from Gedeon Richter Bulgaria, Janssen Pharmaceuticals, Lundbeck, Otsuka, Pfizer and Pierre Fabre.